Connect Biopharma Holdings annual stock-based compensation
2021
2022
2023
2024
2025
Connect Biopharma Holdings Stock-Based Compensation Growth & History (CNTB)
Connect Biopharma Holdings's stock-based compensation was $3.7M for fiscal 2025.
View full Connect Biopharma Holdings company overviewConnect Biopharma Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.7M | −$3.0M | −44.62% |
| 2024 | 2024-12-31 | $6.7M | $1.3M | +24.68% |
| 2023 | 2023-12-31 | $5.4M | −$1.5M | −21.88% |
| 2022 | 2022-12-31 | $6.9M | −$2.1M | −23.14% |
| 2021 | 2021-12-31 | $9.0M | — | — |
Connect Biopharma Holdings quarterly stock-based compensation
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.3M | $310,000 | +32.60% |
| Q1 2026 | 2026-03-31 | $1.2M | $257,000 | +27.28% |
| Q4 2025 | 2025-12-31 | $917,000 | −$484,000 | −34.55% |
| Q3 2025 | 2025-09-30 | $916,000 | −$1.1M | −54.70% |
| Q2 2025 | 2025-06-30 | $951,000 | −$1.0M | −52.19% |
| Q1 2025 | 2025-03-31 | $942,000 | −$374,000 | −28.42% |
| Q4 2024 | 2024-12-31 | $1.4M | — | — |
| Q3 2024 | 2024-09-30 | $2.0M | — | — |
| Q2 2024 | 2024-06-30 | $2.0M | — | — |
| Q1 2024 | 2024-03-31 | $1.3M | — | — |
Connect Biopharma Holdings stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Connect Biopharma Holdings's stock-based compensation decreased from $9.0M to $3.7M, a change of −$5.3M. The latest reported quarter, Q2 2026, shows $1.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Connect Biopharma Holdings source filings ↗